

# Jeffrey A Sparks

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5055813/publications.pdf>

Version: 2024-02-01

188  
papers

8,917  
citations

66343

42  
h-index

53230

85  
g-index

195  
all docs

195  
docs citations

195  
times ranked

11587  
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. <i>New England Journal of Medicine</i> , 2020, 383, 2291-2293.	27.0	1,069
2	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. <i>New England Journal of Medicine</i> , 2019, 380, 752-762.	27.0	886
3	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.9	496
4	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 924-939.	3.4	466
5	Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2019, 170, ITC1.	3.9	464
6	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1108-1123.	5.6	339
7	Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US “hot spot”™. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1156-1162.	0.9	217
8	A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. <i>Annals of Internal Medicine</i> , 2020, 172, 819-821.	3.9	177
9	Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1914-1922.	0.9	168
10	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.9	151
11	Communicating Genetic Risk Information for Common Disorders in the Era of Genomic Medicine. <i>Annual Review of Genomics and Human Genetics</i> , 2013, 14, 491-513.	6.2	135
12	Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow-Up: Results From the Nurses’ Health Study. <i>Arthritis Care and Research</i> , 2016, 68, 753-762.	3.4	133
13	Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis–Associated Interstitial Lung Disease: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 1472-1482.	5.6	129
14	Adverse Effects of Low-Dose Methotrexate. <i>Annals of Internal Medicine</i> , 2020, 172, 369.	3.9	126
15	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2021, 7, e001814.	3.8	121
16	SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2022, 74, 766-775.	5.6	117
17	Long-term dietary quality and risk of developing rheumatoid arthritis in women. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1357-1364.	0.9	105
18	Sugar-sweetened soda consumption and risk of developing rheumatoid arthritis in women , , , . <i>American Journal of Clinical Nutrition</i> , 2014, 100, 959-967.	4.7	98

#	ARTICLE	IF	CITATIONS
19	Osseous sarcoidosis: Clinical characteristics, treatment, and outcomes—Experience from a large, academic hospital. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 371-379.	3.4	87
20	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	5.9	86
21	Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the Nurses' Health Study cohorts. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 196-202.	0.9	79
22	Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 660-666.	0.9	74
23	Genetics, Environment, and Gene-Environment Interactions in the Development of Systemic Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 637-657.	1.9	71
24	Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 289-291.	0.9	69
25	Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 119-123.	0.9	67
26	Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. <i>Arthritis and Rheumatology</i> , 2021, 73, 374-380.	5.6	66
27	Impact of Bariatric Surgery on Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 1619-1626.	3.4	65
28	The Roles of Cigarette Smoking and the Lung in the Transitions Between Phases of Preclinical Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2016, 18, 15.	4.7	61
29	Disclosure of Personalized Rheumatoid Arthritis Risk Using Genetics, Biomarkers, and Lifestyle Factors to Motivate Health Behavior Improvements: A Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2018, 70, 823-833.	3.4	60
30	Impact and Timing of Smoking Cessation on Reducing Risk of Rheumatoid Arthritis Among Women in the Nurses' Health Studies. <i>Arthritis Care and Research</i> , 2019, 71, 914-924.	3.4	60
31	Mobile Apps for Individuals With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 133-141.	0.9	60
32	Interactions Between Amino Acid–Defined Major Histocompatibility Complex Class II Variants and Smoking in Seropositive Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2611-2623.	5.6	58
33	Obesity and the risk of systemic lupus erythematosus among women in the Nurses' Health Studies. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 376-383.	3.4	57
34	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 659-666.	3.0	57
35	Potential of Lifestyle Changes for Reducing the Risk of Developing Rheumatoid Arthritis: Is an Ounce of Prevention Worth a Pound of Cure?. <i>Clinical Therapeutics</i> , 2019, 41, 1323-1345.	2.5	54
36	Influence of Alcohol Consumption on the Risk of Systemic Lupus Erythematosus Among Women in the Nurses' Health Study Cohorts. <i>Arthritis Care and Research</i> , 2017, 69, 384-392.	3.4	53

#	ARTICLE	IF	CITATIONS
37	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. Arthritis and Rheumatology, 2021, 73, 36-47.	5.6	52
38	Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-associated Interstitial Lung Disease. Journal of Rheumatology, 2021, 48, 656-663.	2.0	52
39	A molecular signature of preclinical rheumatoid arthritis triggered by dysregulated PTPN22. JCI Insight, 2016, 1, e90045.	5.0	50
40	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals of the Rheumatic Diseases, 2022, 81, 970-978.	0.9	49
41	Contributions of Familial Rheumatoid Arthritis or Lupus and Environmental Factors to Risk of Rheumatoid Arthritis in Women: A Prospective Cohort Study. Arthritis Care and Research, 2014, 66, 1438-1446.	3.4	47
42	Long-Term Physical Activity and Subsequent Risk for Rheumatoid Arthritis Among Women: A Prospective Cohort Study. Arthritis and Rheumatology, 2019, 71, 1460-1471.	5.6	47
43	Investigating Asthma, Allergic Disease, Passive Smoke Exposure, and Risk of Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1217-1224.	5.6	47
44	Association of fish intake and smoking with risk of rheumatoid arthritis and age of onset: a prospective cohort study. BMC Musculoskeletal Disorders, 2019, 20, 2.	1.9	47
45	Associations of Smoking and Age With Inflammatory Joint Signs Among Unaffected First-Degree Relatives of Rheumatoid Arthritis Patients: Results From Studies of the Etiology of Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1828-1838.	5.6	46
46	Association Between Menopausal Factors and the Risk of Seronegative and Seropositive Rheumatoid Arthritis: Results From the Nurses' Health Studies. Arthritis Care and Research, 2017, 69, 1676-1684.	3.4	44
47	Improved performance of epidemiologic and genetic risk models for rheumatoid arthritis serologic phenotypes using family history. Annals of the Rheumatic Diseases, 2015, 74, 1522-1529.	0.9	43
48	Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology, 2021, 60, 3689-3698.	1.9	43
49	Rheumatoid arthritis and risk of chronic obstructive pulmonary disease or asthma among women: A marginal structural model analysis in the Nurses' Health Study. Seminars in Arthritis and Rheumatism, 2018, 47, 639-648.	3.4	42
50	Inflammatory dietary pattern and risk of developing rheumatoid arthritis in women. Clinical Rheumatology, 2019, 38, 243-250.	2.2	41
51	Asthma, Chronic Obstructive Pulmonary Disease, and Subsequent Risk for Incident Rheumatoid Arthritis Among Women: A Prospective Cohort Study. Arthritis and Rheumatology, 2020, 72, 704-713.	5.6	40
52	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatology, The, 2021, 3, e707-e714.	3.9	40
53	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology, 2022, 61, SI143-SI150.	1.9	40
54	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatology, The, 2021, 3, e855-e864.	3.9	38

#	ARTICLE	IF	CITATIONS
55	SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 817-819.	0.9	37
56	Roles of Postdiagnosis Accumulation of Morbidities and Lifestyle Changes in Excess Total and Cause-Specific Mortality Risk in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 188-198.	3.4	36
57	DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152025.	3.4	36
58	Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Update on Prevalence, Risk Factors, and Pharmacologic Treatment. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 337-353.	1.4	35
59	<i>Festina lente</i> : hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 734-736.	0.9	35
60	Precision medicine in the care of rheumatoid arthritis: Focus on prediction and prevention of future clinically-apparent disease. <i>Autoimmunity Reviews</i> , 2020, 19, 102506.	5.8	34
61	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	3.8	34
62	Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study: Rationale and design for a randomized controlled trial evaluating rheumatoid arthritis risk education to first-degree relatives. <i>Contemporary Clinical Trials</i> , 2014, 39, 145-157.	1.8	33
63	Depression and Subsequent Risk for Incident Rheumatoid Arthritis Among Women. <i>Arthritis Care and Research</i> , 2021, 73, 78-89.	3.4	32
64	SLAMF7 engagement superactivates macrophages in acute and chronic inflammation. <i>Science Immunology</i> , 2022, 7, eabf2846.	11.9	31
65	Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e638-e647.	3.9	30
66	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>Lancet Rheumatology</i> , The, 2022, 4, e237-e240.	3.9	30
67	A Risk Score to Detect Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2022, 74, 1755-1765.	5.6	29
68	Impact of Cyclic Citrullinated Peptide Antibody Level on Progression to Rheumatoid Arthritis in Clinically Tested Cyclic Citrullinated Peptide Antibody-Positive Patients Without Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 1583-1592.	3.4	28
69	Elevated BMI and antibodies to citrullinated proteins interact to increase rheumatoid arthritis risk and shorten time to diagnosis: A nested case-control study of women in the Nurses' Health Studies. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 692-698.	3.4	27
70	Coronavirus Disease 2019 Outcomes Among Recipients of Anti-CD20 Monoclonal Antibodies for Immune-Mediated Diseases: A Comparative Cohort Study. <i>ACR Open Rheumatology</i> , 2022, 4, 238-246.	2.1	27
71	Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 133-142.	3.4	26
72	Phenome-Wide Association Study of Autoantibodies to Citrullinated and Noncitrullinated Epitopes in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 742-749.	5.6	26

#	ARTICLE	IF	CITATIONS
73	Comorbidities As Risk Factors for Rheumatoid Arthritis and Their Accrual After Diagnosis. Mayo Clinic Proceedings, 2019, 94, 2488-2498.	3.0	26
74	Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial. Arthritis and Rheumatology, 2020, 72, 2065-2071.	5.6	26
75	Association of weight loss with improved disease activity in patients with rheumatoid arthritis: A retrospective analysis using electronic medical record data. International Journal of Clinical Rheumatology, 2018, 13, 1-10.	0.3	26
76	Asthma and elevation of anti-citrullinated protein antibodies prior to the onset of rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 246.	3.5	24
77	Circulating plasma metabolites and risk of rheumatoid arthritis in the Nurses' Health Study. Rheumatology, 2020, 59, 3369-3379.	1.9	21
78	Interstitial lung disease throughout the rheumatoid arthritis disease course. Current Opinion in Rheumatology, 2021, 33, 284-291.	4.3	21
79	Predictors of Rheumatic <scp>Immune-Related</scp> Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer. Arthritis and Rheumatology, 2022, 74, 527-540.	5.6	21
80	Effectiveness of a Web-Based Personalized Rheumatoid Arthritis Risk Tool With or Without a Health Educator for Knowledge of Rheumatoid Arthritis Risk Factors. Arthritis Care and Research, 2018, 70, 1421-1430.	3.4	20
81	Smoking Behavior Changes in the Early Rheumatoid Arthritis Period and Risk of Mortality During Thirty-Six Years of Prospective Followup. Arthritis Care and Research, 2018, 70, 19-29.	3.4	20
82	Effect of communicating personalized rheumatoid arthritis risk on concern for developing RA: A randomized controlled trial. Patient Education and Counseling, 2019, 102, 976-983.	2.2	20
83	Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study. Seminars in Arthritis and Rheumatism, 2020, 50, 401-408.	3.4	19
84	Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. Seminars in Arthritis and Rheumatism, 2020, 50, 1191-1201.	3.4	19
85	Association of a Combination of Healthy Lifestyle Behaviors With Reduced Risk of Incident Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2022, 74, 274-283.	5.6	19
86	Passive Smoking Throughout the Life Course and the Risk of Incident Rheumatoid Arthritis in Adulthood Among Women. Arthritis and Rheumatology, 2021, 73, 2219-2228.	5.6	19
87	Inhalants other than personal cigarette smoking and risk for developing rheumatoid arthritis. Current Opinion in Rheumatology, 2020, 32, 279-288.	4.3	19
88	Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries. Seminars in Arthritis and Rheumatism, 2019, 48, 821-827.	3.4	18
89	Rheumatoid arthritis-related lung disease detected on clinical chest computed tomography imaging: Prevalence, risk factors, and impact on mortality. Seminars in Arthritis and Rheumatism, 2020, 50, 1216-1225.	3.4	18
90	Longitudinal Immune Cell Profiling in Patients With Early Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2022, 74, 1808-1821.	5.6	18



#	ARTICLE	IF	CITATIONS
91	Obstructive lung diseases and risk of rheumatoid arthritis. Expert Review of Clinical Immunology, 2020, 16, 37-50.	3.0	17
92	Incident systemic rheumatic disease following COVID-19. Lancet Rheumatology, The, 2021, 3, e402-e404.	3.9	17
93	Validation of claims-based algorithms to identify interstitial lung disease in patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2020, 50, 592-597.	3.4	16
94	Elevated Anti-“Citruinated Protein Antibodies Prior to Rheumatoid Arthritis Diagnosis and Risks for Chronic Obstructive Pulmonary Disease or Asthma. Arthritis Care and Research, 2021, 73, 498-509.	3.4	16
95	Abdominal Obesity in Comparison with General Obesity and Risk of Developing Rheumatoid Arthritis in Women. Journal of Rheumatology, 2021, 48, 165-173.	2.0	15
96	Family History of Rheumatic, Autoimmune, and Nonautoimmune Diseases and Risk of Rheumatoid Arthritis. Arthritis Care and Research, 2021, 73, 180-187.	3.4	15
97	Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases. Current Opinion in Pharmacology, 2022, 65, 102243.	3.5	15
98	Association of Dietary Quality With Risk of Incident Systemic Lupus Erythematosus in the Nurses’ Health Study and Nurses’ Health Study II. Arthritis Care and Research, 2021, 73, 1250-1258.	3.4	14
99	Screening for preclinical parenchymal lung disease in rheumatoid arthritis. Rheumatology, 2022, 61, 3234-3245.	1.9	14
100	Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women’s Health Initiative. PLoS ONE, 2018, 13, e0207509.	2.5	13
101	Cyclooxygenase-2, Asymmetric Dimethylarginine, and the Cardiovascular Hazard From Nonsteroidal Anti-Inflammatory Drugs. Circulation, 2018, 138, 2367-2378.	1.6	13
102	Interactions Between Genome-Wide Genetic Factors and Smoking Influencing Risk of Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 1863-1871.	5.6	13
103	Barriers and Facilitators of Mentoring for Trainees and Early Career Investigators in Rheumatology Research: Current State, Identification of Needs, and Road Map to an Inter-Institutional Adult Rheumatology Mentoring Program. Arthritis Care and Research, 2018, 70, 445-453.	3.4	12
104	Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study. Alimentary Pharmacology and Therapeutics, 2020, 52, 449-458.	3.7	12
105	Protective dietary and hormonal factors brought to light. Nature Reviews Rheumatology, 2018, 14, 71-72.	8.0	11
106	Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry. Clinical Rheumatology, 2019, 38, 3401-3412.	2.2	11
107	Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662110397.	2.6	11
108	Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 3197-3207.	6.1	11

#	ARTICLE	IF	CITATIONS
109	Association of Sinusitis and Upper Respiratory Tract Diseases With Incident Rheumatoid Arthritis: A Case-control Study. <i>Journal of Rheumatology</i> , 2022, 49, 358-364.	2.0	11
110	Weight Change During the Early Rheumatoid Arthritis Period and Risk of Subsequent Mortality in Women With Rheumatoid Arthritis and Matched Comparators. <i>Arthritis and Rheumatology</i> , 2018, 70, 18-29.	5.6	10
111	Relationship Between Rheumatoid Arthritis and Pulmonary Function Measures on Spirometry in the UK Biobank. <i>Arthritis and Rheumatology</i> , 2021, 73, 1994-2002.	5.6	10
112	Prevalence and risk factors of bronchiectasis in rheumatoid arthritis: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1067-1080.	3.4	10
113	Immunosuppression and SARS-CoV-2 breakthrough infections. <i>Lancet Rheumatology</i> , The, 2022, , .	3.9	10
114	Association Between Anti-“CitruLLinated Fibrinogen Antibodies and Coronary Artery Disease in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 1113-1117.	3.4	9
115	Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment. <i>Arthritis Care and Research</i> , 2019, 71, 512-520.	3.4	9
116	Associations between Smoking and Systemic Lupus Erythematosus (SLE)-Related Cytokines and Chemokines among US Female Nurses. <i>Arthritis Care and Research</i> , 2020, 73, 1583-1589.	3.4	9
117	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114.	2.0	9
118	Association of Healthy Lifestyle Behaviors and the Risk of Developing Rheumatoid Arthritis Among Women. <i>Arthritis Care and Research</i> , 2023, 75, 272-276.	3.4	9
119	Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy. <i>RMD Open</i> , 2022, 8, e002082.	3.8	9
120	Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014. <i>Arthritis and Rheumatology</i> , 2016, 68, 1588-1595.	5.6	8
121	Associations between daily alcohol consumption and systemic lupus erythematosus-related cytokines and chemokines among US female nurses without SLE. <i>Lupus</i> , 2020, 29, 976-982.	1.6	8
122	Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2. <i>Critical Care</i> , 2020, 24, 182.	5.8	8
123	Response to: “Correspondence on “SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease” by C<i>et al</i>”. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e131-e131.	0.9	8
124	Assessing the Severity of COVID-19 Lung Injury in Rheumatic Diseases Versus the General Population Using Deep Learning-Derived Chest Radiograph Scores. <i>Arthritis Care and Research</i> , 2023, 75, 657-666.	3.4	8
125	Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by van Vollenhoven<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e178-e178.	0.9	7
126	Musculoskeletal and pulmonary outcomes of sarcoidosis after initial presentation of osseous involvement. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2019, 36, 60-73.	0.2	7



#	ARTICLE	IF	CITATIONS
127	The impact of COVID-19 on rheumatology training—results from the COVID-19 Global Rheumatology Alliance trainee survey. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkac001.	0.7	7
128	Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. <i>Rheumatology</i> , 2022, 61, SI151-SI156.	1.9	7
129	Circulating blood metabolite trajectories and risk of rheumatoid arthritis among military personnel in the Department of Defense Biorepository. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 989-996.	0.9	6
130	Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. <i>Current Opinion in Rheumatology</i> , 2021, 33, 412-418.	4.3	6
131	Circulating carotenoids and subsequent risk of rheumatoid arthritis in women. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 309-312.	0.8	6
132	Rapid Adoption of Telemedicine in Rheumatology Care During the COVID-19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. <i>ACR Open Rheumatology</i> , 2022, 4, 128-133.	2.1	6
133	Associations of the MUC5B promoter variant with timing of interstitial lung disease and rheumatoid arthritis onset. <i>Rheumatology</i> , 2022, 61, 4915-4923.	1.9	6
134	A Roadmap for Investigating Preclinical Autoimmunity Using Patient-Oriented and Epidemiologic Study Designs: Example of Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	6
135	Administrative Algorithms to identify Avascular necrosis of bone among patients undergoing upper or lower extremity magnetic resonance imaging: a validation study. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 268.	1.9	5
136	Utilizing a PTPN22 gene signature to predict response to targeted therapies in rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2019, 101, 121-130.	6.5	5
137	Incidence and Predictors of Dyspnea on Exertion in a Prospective Cohort of Patients With Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 4-15.	2.1	5
138	Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101658.	3.3	5
139	Assessing improved risk prediction of rheumatoid arthritis by environmental, genetic, and metabolomic factors. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1016-1022.	3.4	5
140	Systemic sarcoidosis presenting as Harlequin and Horner syndrome. <i>Neurology: Clinical Practice</i> , 2015, 5, 524-527.	1.6	4
141	A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic. <i>ACR Open Rheumatology</i> , 2020, 2, 491-495.	2.1	4
142	Response to: “Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?” by Erre et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e30-e30.	0.9	4
143	Response to: “COVID-19 in patients with rheumatological diseases treated with Anti-TNF by Brito et al and “Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China “hot spot” versus in US “hot spot”: similarities and differences” by Zhao et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e64-e64.	0.9	4
144	Challenges and Opportunities of Targeted Behavioral Interventions for Groups at Risk for Developing Rheumatoid Arthritis. <i>Healthcare (Switzerland)</i> , 2021, 9, 641.	2.0	4

#	ARTICLE	IF	CITATIONS
145	Towards clinical significance of the <i>MUC5B</i> promoter variant and risk of rheumatoid arthritis-associated interstitial lung disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1503-1504.	0.9	4
146	Annals On Call - COVID-19: Is Chloroquine the Answer?. <i>Annals of Internal Medicine</i> , 2020, 172, OC1.	3.9	4
147	Therapeutic Drug Monitoring for Immune-Mediated Inflammatory Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2370.	7.4	4
148	Can we finally exonerate methotrexate as a factor in causing or exacerbating fibrotic interstitial lung disease in patients with rheumatoid arthritis?. <i>Clinical Rheumatology</i> , 2022, 41, 2925-2928.	2.2	4
149	Adverse Effects of Low-Dose Methotrexate. <i>Annals of Internal Medicine</i> , 2020, 173, 167.	3.9	3
150	Response to: "COVID-19 in patients with rheumatic diseases: what is the real mortality risk?" by Marques<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e135-e135.	0.9	3
151	Investigating the impact of disease and health record duration on the eMERGE algorithm for rheumatoid arthritis. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 601-605.	4.4	3
152	Long-term weight changes and risk of rheumatoid arthritis among women in a prospective cohort: a marginal structural model approach. <i>Rheumatology</i> , 2022, 61, 1430-1439.	1.9	3
153	Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process. <i>Seminars in Arthritis and Rheumatism</i> , 2021, , .	3.4	3
154	Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e158-e158.	0.9	3
155	Improving sensitivity of the connective tissue disease screening questionnaire: A comparative study of various scoring methods. <i>Lupus</i> , 2021, 30, 35-44.	1.6	3
156	Timing of sinusitis and other respiratory tract diseases and risk of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151937.	3.4	3
157	Interstitial Pneumonia with Autoimmune Features: What the Rheumatologist Needs to Know. <i>Current Rheumatology Reports</i> , 0, , .	4.7	3
158	Quantitative chest imaging and prediction of mortality in rheumatoid arthritis-associated interstitial lung disease. <i>Rheumatology</i> , 0, , .	1.9	3
159	Association of Ultraviolet B Radiation and Risk of Systemic Lupus Erythematosus Among Women in the Nurses' Health Studies. <i>Arthritis Care and Research</i> , 2023, 75, 1409-1415.	3.4	3
160	Smoking association with influenza infection in renal transplant recipients. <i>Transplant Infectious Disease</i> , 2014, 16, 153-157.	1.7	2
161	Monoarthritis in a 28-Year-Old Man With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 1328-1334.	3.4	2
162	Reply. <i>Arthritis Care and Research</i> , 2016, 68, 1211-1212.	3.4	2

#	ARTICLE	IF	CITATIONS
163	Response to: <i>Correspondence on Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist</i> by Graef et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e164-e164.	0.9	2
164	Response to: <i>Case series of acute arthritis in COVID-19 admission</i> by L3pez-Gonz3lez et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e59-e59.	0.9	2
165	Pregnancy after bariatric surgery in women with rheumatic diseases and association with adverse birth outcomes. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 406-413.	1.2	2
166	Isolated gastric sarcoidosis: a rare entity. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-219682.	0.5	2
167	Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA) associated Bronchiectasis: Role of RA-related Autoantibodies. <i>Journal of Rheumatology</i> , 2022, 49, 672-679.	2.0	2
168	Any Given Monday: Association Between Desk Rejections and Weekend Manuscript Submissions to Rheumatology Journals. <i>Journal of Rheumatology</i> , 2022, 49, 652-653.	2.0	2
169	Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment. <i>Lancet Respiratory Medicine</i> , 2022, 10, 813-815.	10.7	2
170	Reply. <i>Arthritis and Rheumatology</i> , 2018, 70, 627-628.	5.6	1
171	OP0088...COMORBIDITIES AS RISK FACTORS FOR RHEUMATOID ARTHRITIS (RA) AND ACCRUAL AFTER RA DIAGNOSIS. , 2019, , .		1
172	Response to: <i>Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors</i> by Jovani et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e132-e132.	0.9	1
173	No association between recent antibiotic use and risk of rheumatoid arthritis: results from two prospective cohort studies. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 121-126.	2.4	1
174	Clinical application of personalized rheumatoid arthritis risk information: translational epidemiology leading to precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 147-149.	0.7	1
175	Neurosarcoidosis. , 2019, , 73-85.		0
176	THU0689...ASTHMA AND ELEVATION OF ANTI-CITRULLINATED PROTEIN ANTIBODIES PRIOR TO THE ONSET OF RHEUMATOID ARTHRITIS. , 2019, , .		0
177	SAT0072...EVALUATION OF RHEUMATOID ARTHRITIS TREATMENTS AND JOINT OUTCOMES IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE. , 2019, , .		0
178	THU0085...RHEUMATOID ARTHRITIS AND ALLERGIC DISEASES. , 2019, , .		0
179	No association of bariatric surgery with reduced rheumatoid arthritis risk: where do we go from here?. <i>Rheumatology</i> , 2020, 59, 275-276.	1.9	0
180	Response to: <i>Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis</i> by Singer et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e162-e162.	0.9	0

#	ARTICLE	IF	CITATIONS
181	Response to: “Emergency arising from patients’ fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?” by Santos-Moreno <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e155-e155.	0.9	0
182	Reply to “Taking a stand against the politicization of medical research: how “swinging the pendulum” poses a hazard to clinical trials, study participants, and the progress of science”. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 105-107.	3.0	0
183	Health risk assessment and family history: Toward disease prevention. , 2021, , 215-236.		0
184	Multimorbidity Accrual After Incident Rheumatoid Arthritis: A Wolf at the Door. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.210224.	2.0	0
185	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 1767-1768.	5.6	0
186	Reply. <i>Arthritis and Rheumatology</i> , 2022, 74, 543-544.	5.6	0
187	Reply. <i>Arthritis and Rheumatology</i> , 2022, 74, 1096-1097.	5.6	0
188	Effectiveness of COVID-19 vaccination in immune-mediated inflammatory diseases. <i>Lancet Rheumatology</i> , The, 2022, , .	3.9	0